Cobicistat

證據等級: L5

預測適應症: 10 個

Cobicistat: From Adult HIV Treatment to Congenital HIV Management

One-Sentence Summary

Cobicistat is a selective CYP3A inhibitor approved as a pharmacokinetic booster within HIV fixed-dose combination regimens (E/C/F/TAF and D/C/F/TAF), used to amplify plasma concentrations of co-administered antiretrovirals in adult HIV therapy. TxGNN predicts it may contribute to the management of Congenital Human Immunodeficiency Virus — vertically acquired HIV infection in neonates and children — with 12 clinical trials and 2 publications currently supporting this direction, including multiple large-scale Phase 3 RCTs (Evidence Level: L1).

TxGNN’s rank #1 prediction was simian immunodeficiency virus infection (SIV, 99.92%), a non-human primate disease with no human clinical applicability. This report focuses on the most clinically actionable prediction: Rank #5 — Congenital HIV (98.33%, L1, Proceed with Guardrails).

Quick Overview

Item	Content
Original Indication	HIV treatment (pharmacokinetic booster component in E/C/F/TAF and D/C/F/TAF regimens)
Predicted New Indication	Congenital Human Immunodeficiency Virus
TxGNN Prediction Score	98.33% (Rank #5; Rank #1 SIV is a non-human primate disease — clinically inapplicable)
Evidence Level	L1
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data from DrugBank is not available for this report. Based on established clinical pharmacology, cobicistat is a mechanistic inhibitor of CYP3A4 and intestinal P-glycoprotein (P-gp) with no intrinsic antiretroviral activity of its own. Its sole clinical purpose is pharmacokinetic boosting: by blocking the metabolic enzymes that would otherwise rapidly eliminate co-administered drugs, cobicistat dramatically increases their plasma exposure — raising darunavir Cmin by approximately 10-fold and elvitegravir AUC by approximately 20-fold — thereby enabling effective once-daily dosing regimens.

Congenital HIV results from mother-to-child vertical transmission during pregnancy, delivery, or breastfeeding. Prevention depends critically on sustained maternal HIV RNA suppression throughout gestation. For infants and children who are already infected, cobicistat-containing fixed-dose combinations (particularly E/C/F/TAF [Genvoya] in adolescents ≥12 years) provide an effective single-tablet regimen option. Multiple Phase 3 RCTs — NCT02269917 (n=1,149) and NCT02431247 (n=725) — establish robust virological suppression data for D/C/F/TAF in adults, directly applicable to maternal HIV management to prevent vertical transmission. Dedicated Phase 2/3 data from NCT01854775 (n=129) specifically evaluated E/C/F/TAF in HIV-infected adolescents and children, bridging adult data to younger populations.

The key mechanistic caveat is that cobicistat’s own pharmacokinetics change substantially during pregnancy: increased hepatic and intestinal metabolic activity in the second and third trimesters reduces cobicistat plasma levels, potentially compromising its boosting function and leading to subtherapeutic antiretroviral concentrations. This pregnancy-related PK vulnerability is the primary guardrail — not lack of efficacy. Current DHHS Perinatal HIV Guidelines advise against initiating cobicistat-boosted regimens in pregnant patients who are not already stably maintained on them; patients who conceive while virologically suppressed may continue with enhanced therapeutic drug monitoring.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02269917	Phase 3	Completed	1,149	Randomized switch study: D/C/F/TAF vs boosted PI + FTC/TDF in virologically-suppressed HIV-1 patients; demonstrated non-inferiority in HIV-1 RNA suppression (<50 copies/mL) at Week 48 with improved renal and bone safety profile
NCT02431247	Phase 3	Completed	725	Double-blind RCT: D/C/F/TAF vs DRV/COBI + FTC/TDF in treatment-naive HIV-1 adults; confirmed non-inferior virological efficacy, establishing cobicistat-boosted D/C/F/TAF as a first-line HIV treatment option
NCT01854775	Phase 2/3	Completed	129	E/C/F/TAF PK, safety, and antiviral activity in HIV-1 infected treatment-naive adolescents (≥12 years) and virologically-suppressed children; confirmed dose selection and efficacy at Week 24, directly supporting cobicistat use in pediatric HIV populations
NCT00855335	Phase 3	Completed	77	Single-arm PK comparison of darunavir/ritonavir vs darunavir/cobicistat in HIV-1 infected pregnant women; key dataset for understanding cobicistat’s pregnancy-related PK changes and their implications for vertical transmission prevention
NCT04518228	N/A	Completed	205	Longitudinal ARV and anti-TB drug PK study across pregnancy trimesters and postpartum; provides cobicistat PK trajectory data critical for maternal HIV management strategy design
NCT03577470	N/A	Completed	246	DIAMANTE: Italian retrospective + prospective real-world observational study of D/C/F/TAF effectiveness (n=246); 48-week virological response data confirm real-world durability of cobicistat-boosted regimen
NCT04442737	Phase 4	Completed	103	Switch to D/C/F/TAF in virologically-suppressed patients with rapid weight gain on INI+TAF/FTC regimens; safety and metabolic profile data with cobicistat-containing regimen at Week 48
NCT00042289	N/A	Completed	1,578	IMPAACT P1026s: large-scale prospective PK study of ARV drugs in pregnant women and infants; includes cobicistat-containing regimens, directly informing perinatal HIV management and congenital HIV prevention strategies
NCT03045861	Phase 2	Completed	33	Cobicistat-boosted GSK2838232 (novel HIV-1 maturation inhibitor) 10-day dose-ranging monotherapy; confirms cobicistat’s expandable role as a PK booster for emerging HIV agents beyond darunavir and elvitegravir
NCT02397096	Phase 3	Completed	673	Doravirine switch study from ritonavir/cobicistat-boosted PI regimens; cobicistat serves as background control, providing comparative safety and virological reference data

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33048878	2021	Cohort	AIDS	Risk of birth defects and adverse perinatal outcomes in HIV-infected women exposed to integrase strand transfer inhibitors (INSTIs) at conception; contextualizes safety trade-offs when selecting between INSTI- vs cobicistat-boosted regimens for women of childbearing potential and pregnant patients
35809963	2022	Case Report	Chest	28-year-old man with congenital HIV presenting with diffuse bilateral pulmonary nodules and encephalopathy; illustrates long-term complications of vertically acquired HIV and the ongoing clinical need for effective, durable ARV regimen selection across the entire lifespan

Safety Considerations

Please refer to the SmPC for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple Phase 3 RCTs establish robust virological suppression data for cobicistat-containing fixed-dose combinations (D/C/F/TAF, E/C/F/TAF) in adults — directly relevant to maternal HIV management for preventing vertical transmission — and Phase 2/3 data specifically support use in adolescents ≥12 years; the primary barrier to broader application in congenital HIV is cobicistat’s own pregnancy-related PK vulnerability, not insufficient evidence of antiretroviral efficacy in the target population.

To proceed, the following is needed:

Trimester-specific PK studies confirming adequate cobicistat boosting effect throughout pregnancy, with therapeutic drug monitoring protocols and defined viral load thresholds for regimen reassessment
Weight-band–based pediatric dosing studies for children <12 years receiving cobicistat-boosted regimens
Neonatal PK characterization of cobicistat and boosted antiretrovirals in HIV-exposed newborns
Taiwan (TFDA) regulatory submission for cobicistat-containing fixed-dose combination products (currently 0 domestic authorizations)
Safety monitoring plan addressing renal function, bone mineral density (especially in pediatric populations), extensive DDI screening given cobicistat’s potent CYP3A4/P-gp inhibition, and trimester-specific viral load tracking during pregnancy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.